Anti-Human EGFR x MET (Amivantamab) (E340-GRP)

Anti-Human EGFR x MET bispecific antibodies have shown promising results in cancer therapy. These antibodies target both the epidermal growth factor receptor (EGFR) and the MET receptor, which are crucial in cancer progression and resistance mechanisms. Studies have demonstrated that bispecific antibodies can inhibit proliferation, migration, and invasive growth of tumor cells more effectively than single-agent treatments. Additionally, these antibodies have been found to enhance tumor growth inhibition and downregulate both EGFR and MET receptors, highlighting their potential in combating therapeutic resistance in patients with EGFR mutations. The combination of EGFR and MET inhibition through bispecific antibodies presents a valuable strategy for overcoming resistance mechanisms and improving treatment outcomes in cancer patients1-3. Amivantamab (JNJ-611) is a human bispecific monoclonal antibody that targets both the EGFR and the hepatocyte growth factor receptor (HGFR/cMet). This bispecific antibody is engineered to simultaneously bind to wild-type and mutant forms of EGFR and MET, thereby blocking their phosphorylation and subsequent signaling pathways essential for cancer cell proliferation. Preclinical studies demonstrated the superior efficacy of Amivantamab in models with EGFR exon 20 insertions compared to other therapies like cetuximab or poziotinib. In clinical settings, Amivantamab has shown promise in treating patients with NSCLC, particularly those with EGFR exon 20 insertion mutations who have progressed after platinum-based chemotherapy1,3.